GSK (LON:GSK – Get Free Report)‘s stock had its “hold” rating reissued by equities research analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Monday,London Stock Exchange reports. They currently have a GBX 1,900 price target on the stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential downside of 1.04% from the company’s current price.
Several other analysts have also recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a report on Thursday, May 28th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Citigroup reduced their target price on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Finally, Berenberg Bank reiterated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Thursday, March 26th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of GBX 2,034.29.
Check Out Our Latest Stock Report on GSK
GSK Stock Performance
GSK (LON:GSK – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The company had revenue of GBX 762.90 billion for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. As a group, analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.
Insider Transactions at GSK
In related news, insider Jonathan Symonds purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was acquired at an average price of GBX 1,951 per share, for a total transaction of £97,550. Also, insider Wendy Becker purchased 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were bought at an average price of GBX 1,963 per share, with a total value of £78,520. Insiders have bought 9,619 shares of company stock valued at $19,452,794 over the last ninety days. 0.31% of the stock is owned by company insiders.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Further Reading
- Five stocks we like better than GSK
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
